Radiolabelled IV and Oral Metabolism Study of F901318

Invasive Aspergillosis Clinical Trial

— ADME  

Official title:

An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-F901318 Administered Via the Intravenous and Oral Routes to Healthy Male Subjects

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02912026
• Other study ID #: F901318-01-08-16
• Status: Withdrawn
• Phase: Phase 1
• Start date: May 2019
• Est. completion date: July 2019

Study information

• Verified date: July 2018
• Source: F2G Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label radiolabelled metabolism study of intravenous and oral solution forms of F901318. Five healthy male subjects will receive IV and five will receive an oral solution. Blood, urine and faeces will be collected over a period adequate to obtain 90% recovery of parent compound and to determine the metabolic profile of both IV and oral forms.

Description:

Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. Eligible subjects will be admitted to the clinical unit on the evening of Day -1 prior to investigational medicinal product (IMP) administration, and will be dosed on the morning of Day 1. In Cohort 1 (Regimen A), subjects will be dosed after a light breakfast; to assess tolerability of the IV administration, the first subject will be dosed at least 30 min prior to dosing the second subject. All subsequent dosing of the IV formulation will be staggered by at least 15 min. In Cohort 2 (Regimen B), subjects will be dosed following an overnight fast with an appropriate interval between subjects based on logistical requirements. Subjects will remain resident in the clinic up to 336 h post-dose (Day 15). It is planned that subjects will return to the clinical unit for 2 further 24 h residency periods on Day 21 and Day 28 if discharge criteria outlined in this protocol are not met. It is planned that subjects will be released from the study as a group when all subjects have achieved a mass balance cumulative recovery of >90% or <1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 h periods. If this occurs earlier than Day 28, collection of all samples (blood, urine and faeces) will be stopped and the subjects will undergo discharge assessments. If this criterion has not been met by all subjects following the Day 28 return visit, home collections of urine and faeces may be requested at the discretion of the investigator for individual subjects.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males who do not wish to father children within the 6 months following IMP administration.

2. Age 40 to 65 years of age at the time of signing the ICF.

3. Body mass index of 18.0 to 35.0 kg/m2, with a weight of 50 to 100 kg.

4. Must be willing and able to communicate and participate in the whole study.

5. Subjects must be in good health as determined by a medical history, physical examination, 12-lead ECG and clinical laboratory evaluations.

6. Must have regular bowel movements (ie, average stool production of =1 and =3 stools per day).

7. Must provide written informed consent and agree to abide by the study restrictions

8. Must agree to use an adequate method of contraception during the study and for 6 months after study discharge

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months prior to dosing.

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.

3. Subjects who have previously been enrolled in this study or have previously been exposed to F901318.

4. History of any drug or alcohol abuse in the past 2 years.

5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).

6. Current smokers and those who have smoked or used nicotine containing products (eg electronic cigarettes) within the last 6 months. A confirmed positive urine cotinine test at screening or admission.

7. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.

8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.

Related Conditions & MeSH terms

• Aspergillosis
• Invasive Aspergillosis

Intervention

Drug:
• IV F901318
Metabolic profile AUC 0 to infinity
• Oral F901318
Metabolic profile AUC 0 to infinity

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical	Nottingham	Nottinghamshire

Sponsors (2)

Lead Sponsor	Collaborator
F2G Ltd.	Quotient Clinical

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mass balance	Metabolic profiling over 28 days	28 days